Clinical Trial Update: Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update describing a Phase 2/3 study evaluating Fruquintinib plus Sintilimab and SBRT for second-line or higher treatment of gastric or gastroes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Queling Liu | Conditions: Gastric Neoplasm | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING